Slc6a8-flox Mouse
一般名
Slc6a8-flox
製品ID
S-CKO-00300
背景情報
C57BL/6JCya
系統ID
CKOCMP-102857-Slc6a8-B6J-VA
状況
このマウス系統を論文で使用する場合は、「Slc6a8-flox Mouse(カタログ番号S-CKO-00300)はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
基本情報
系統名
Slc6a8-flox
系統ID
CKOCMP-102857-Slc6a8-B6J-VA
遺伝子名
製品ID
S-CKO-00300
遺伝子別名
CRT, CT1, CRTR, CTR5, Creat
遺伝子別名
C57BL/6JCya
NCBI ID
修正
Conditional knockout
染色体
Chr X
表現型
アプリケーション
--
さらに
系統詳細
EnsemblトランスクリプトID
ENSMUST00000033752
NCBIトランスクリプトID
NM_133987
ターゲット領域
Exon 3~4
有効領域の大きさ
~1.8 kb
遺伝子研究の概要
Slc6a8, encoding a membrane protein, is a creatine transporter that moves creatine in and out of cells in a Na+ and Cl--dependent manner [4,6]. Creatine is a key source of cellular energy reserve, and thus Slc6a8 is crucial for maintaining normal cellular energy metabolism. It is also associated with multiple biological processes, and its deficiency can lead to various disorders [1,3,7]. Genetic models, such as knockout (KO) mouse models, are valuable for studying its functions.
Depletion of intracellular creatine by ablation of Slc6a8 in KO mouse models altered macrophage-mediated immune responses in vivo, uncovering a role for creatine in macrophage polarization by modulating responses to cytokines like IFN-γ and IL-4 [1]. In colon cancer, the SLC6A8 inhibitor RGX-202 robustly inhibits creatine import in vitro and in vivo, reduces intracellular phosphocreatine and ATP levels, and induces tumor apoptosis, suppressing CRC growth across different xenograft models [2]. In females with X-linked creatine transporter deficiency caused by pathogenic variants in SLC6A8, oral supplementation treatment showed potential for clinical improvement [3]. In lung adenocarcinoma, high expression of SLC6A8 was associated with poor survival and its genetic alteration was also related to a poorer prognosis [4]. In non-small cell lung cancer, SLC6A8 overexpression promotes the proliferation, migration and invasion in vitro, accompanied by the activation of notch signaling pathway, while knocking down SLC6A8 can inhibit these effects [5]. In human hepatocellular carcinoma, SLC6A8 knockdown significantly induced apoptosis and suppressed the migration and invasion of Hep3B and Huh-7 cells [6]. In triple-negative breast cancer, SLC6A8-mediated creatine accumulation promoted cell survival and suppressed apoptosis in hypoxic conditions, and was required to facilitate tumor growth in xenograft mouse models [8].
In conclusion, Slc6a8 plays a vital role in multiple biological processes and diseases through its function of transporting creatine. Model-based research, especially KO/CKO mouse models, has revealed its significant contributions to macrophage polarization, cancer progression (such as colon, lung, liver, and breast cancer), and creatine-related deficiency disorders. Understanding Slc6a8 functions provides potential therapeutic targets for these diseases.
References:
1. Ji, Liangliang, Zhao, Xinbin, Zhang, Bin, Chen, Ligong, Hu, Xiaoyu. 2019. Slc6a8-Mediated Creatine Uptake and Accumulation Reprogram Macrophage Polarization via Regulating Cytokine Responses. In Immunity, 51, 272-284.e7. doi:10.1016/j.immuni.2019.06.007. https://pubmed.ncbi.nlm.nih.gov/31399282/
2. Kurth, Isabel, Yamaguchi, Norihiro, Andreu-Agullo, Celia, Tavazoie, Masoud F, Tavazoie, Sohail F. 2021. Therapeutic targeting of SLC6A8 creatine transporter suppresses colon cancer progression and modulates human creatine levels. In Science advances, 7, eabi7511. doi:10.1126/sciadv.abi7511. https://pubmed.ncbi.nlm.nih.gov/34613776/
3. Mejdahl Nielsen, Malene, Petersen, Esben Thade, Fenger, Christina Dühring, Grønborg, Sabine Weller, Hammer, Trine Bjørg. 2023. X-linked creatine transporter (SLC6A8) deficiency in females: Difficult to recognize, but a potentially treatable disease. In Molecular genetics and metabolism, 140, 107694. doi:10.1016/j.ymgme.2023.107694. https://pubmed.ncbi.nlm.nih.gov/37708665/
4. Fan, Yongfei, Zhou, Yong, Lou, Ming, Li, Xinwei, Yuan, Kai. 2022. SLC6A8 is a Potential Biomarker for Poor Prognosis in Lung Adenocarcinoma. In Frontiers in genetics, 13, 845373. doi:10.3389/fgene.2022.845373. https://pubmed.ncbi.nlm.nih.gov/35692837/
5. Feng, Yan, Guo, Xiangyu, Tang, Huaping. . SLC6A8 is involved in the progression of non-small cell lung cancer through the Notch signaling pathway. In Annals of translational medicine, 9, 264. doi:10.21037/atm-20-5984. https://pubmed.ncbi.nlm.nih.gov/33708891/
6. Yuan, Lu, Wu, Xian Jian, Li, Wen Chuan, Wang, JianChu, Pu, Jian. . SLC6A8 Knockdown Suppresses the Invasion and Migration of Human Hepatocellular Carcinoma Huh-7 and Hep3B Cells. In Technology in cancer research & treatment, 19, 1533033820983029. doi:10.1177/1533033820983029. https://pubmed.ncbi.nlm.nih.gov/33356959/
7. Braissant, O, Henry, H. 2008. AGAT, GAMT and SLC6A8 distribution in the central nervous system, in relation to creatine deficiency syndromes: a review. In Journal of inherited metabolic disease, 31, 230-9. doi:10.1007/s10545-008-0826-9. https://pubmed.ncbi.nlm.nih.gov/18392746/
8. Li, Qiao, Liu, Manran, Sun, Yan, Hou, Yixuan, Tu, Gang. 2021. SLC6A8-mediated intracellular creatine accumulation enhances hypoxic breast cancer cell survival via ameliorating oxidative stress. In Journal of experimental & clinical cancer research : CR, 40, 168. doi:10.1186/s13046-021-01933-7. https://pubmed.ncbi.nlm.nih.gov/33990217/
品質管理基準
精子検査
凍結前の精子濃度を測定し、精子の生存能力の判定します。
凍結後の精子では、各バッチから1本の凍結保存された精子を選び出し、体外受精に使用します。
環境基準:
SPF対応地域:
グローバル由来:
Cyagenお問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。
